AB 02 Impact of Persistent Symptoms on Quality of Life in Long COVID - David Lerma Irureta
11:32
AB 02 Impact of Persistent Symptoms on Quality of Life in Long COVID - David Lerma Irureta
Ай бұрын
Viral Persistence & Long COVID: Lessons Learned from the First Clinical Trials - Michael Peluso, MD
23:23
Viral Persistence & Long COVID: Lessons Learned from the First Clinical Trials - Michael Peluso, MD
Ай бұрын
Long COVID Therapeutic Trials: Current Status - Dominique Salmon, MD, PhD
19:28
Long COVID Therapeutic Trials: Current Status - Dominique Salmon, MD, PhD
Ай бұрын
French Example - Jérôme Larché, MD, MSc
13:49
French Example - Jérôme Larché, MD, MSc
Ай бұрын
Lessons Learned from Observational Studies for Future Clinical Trials- Igho Ofotokun, MD, MSc, FIDSA
19:24
Lessons Learned from Observational Studies for Future Clinical Trials- Igho Ofotokun, MD, MSc, FIDSA
Ай бұрын
Molecular PET Imaging of Long COVID - Eric Guedj, MD, Dipl.-Ing, PhD
21:20
Molecular PET Imaging of Long COVID - Eric Guedj, MD, Dipl.-Ing, PhD
Ай бұрын
AB 06 Unraveling Molecular Signature of Long COVID with Post-Exertional Fatigue - Marta Massanella
9:01
AB 06 Unraveling Molecular Signature of Long COVID with Post-Exertional Fatigue - Marta Massanella
Ай бұрын
AB 01 Clinical Insights From a Pediatric Long COVID Clinic - Sindhu Mohanadas, United States
14:16
AB 01 Clinical Insights From a Pediatric Long COVID Clinic - Sindhu Mohanadas, United States
Ай бұрын
Dutch Example - Mischa Huson, MD, PhD, DTM&H
8:35
Dutch Example - Mischa Huson, MD, PhD, DTM&H
Ай бұрын
AB 07 Sub-Maximal 2-day Cardiopulmonary Exercise Testing - Callum Thomas
9:31
AB 07 Sub-Maximal 2-day Cardiopulmonary Exercise Testing - Callum Thomas
Ай бұрын
Immune Dysregulation and Autoimmunity in Long COVID - Daniel M. Altmann, PhD
22:39
Immune Dysregulation and Autoimmunity in Long COVID - Daniel M. Altmann, PhD
Ай бұрын
AB 03 Long COVID and Associated Outcomes Following COVID-19 Reinfections - Assaf & Soares
10:09
AB 03 Long COVID and Associated Outcomes Following COVID-19 Reinfections - Assaf & Soares
Ай бұрын
AB 10 Anticoagulant and Antiviral Therapy in Long COVID - Johan van Weyenbergh
12:57
AB 10 Anticoagulant and Antiviral Therapy in Long COVID - Johan van Weyenbergh
Ай бұрын
Case 1: Differential Diagnosis - Gemma Lladós, MD
11:43
Case 1: Differential Diagnosis - Gemma Lladós, MD
Ай бұрын
Long COVID: State of the Science and Directions for Policy and Research - Roger Paredes, MD, PhD
35:13
Long COVID: State of the Science and Directions for Policy and Research - Roger Paredes, MD, PhD
Ай бұрын
Epidemiology and Long Term Evolution of Long COVID - Olivier Robineau, MD, PhD
22:52
Epidemiology and Long Term Evolution of Long COVID - Olivier Robineau, MD, PhD
Ай бұрын
Patient Perspective on Clinical Trials Design - Chantal Britt, MA
25:51
Patient Perspective on Clinical Trials Design - Chantal Britt, MA
Ай бұрын
Autonomic Dysfunction in Long COVID - Nicola Montano, PhD
29:37
Autonomic Dysfunction in Long COVID - Nicola Montano, PhD
Ай бұрын
AB 11 Exploring the Efficacy of Plasma Exchange Therapy in Post-COVID-19 - Sergio España Cueto
11:11
AB 11 Exploring the Efficacy of Plasma Exchange Therapy in Post-COVID-19 - Sergio España Cueto
Ай бұрын
AB 04 An Innovative Digital Health Solution to Address Unmet Needs in Long COVID - Fischer & Oustric
9:22
AB 04 An Innovative Digital Health Solution to Address Unmet Needs in Long COVID - Fischer & Oustric
Ай бұрын
Prospects for Gene Editing in CHB Cure Regimens - Fabien Zoulim, MD, PhD
23:57
Prospects for Gene Editing in CHB Cure Regimens - Fabien Zoulim, MD, PhD
Ай бұрын
Strategies and Potential for siRNA + ASO Combinations - Dickens Theodore, MD, MPH
11:44
Strategies and Potential for siRNA + ASO Combinations - Dickens Theodore, MD, MPH
Ай бұрын
Next Generation Tests for HBcAg and HBcrAg - Increased Sensitivity and Utility? - Mark Sulkowski, MD
22:33
Next Generation Tests for HBcAg and HBcrAg - Increased Sensitivity and Utility? - Mark Sulkowski, MD
Ай бұрын
Imdusiran Combinations Achieving HBsAg Loss - Karen Sims, MD, PhD
11:29
Imdusiran Combinations Achieving HBsAg Loss - Karen Sims, MD, PhD
Ай бұрын
Efficacy of Cams across Patient Cohorts: HBeAg+ vs. HBeAg- - Tse-I Lin, D.Phil
13:57
Efficacy of Cams across Patient Cohorts: HBeAg+ vs. HBeAg- - Tse-I Lin, D.Phil
Ай бұрын
Sustainability of HBsAg Loss After Treatment: Functional Cure - Harry Janssen, MD, PhD
21:31
Sustainability of HBsAg Loss After Treatment: Functional Cure - Harry Janssen, MD, PhD
Ай бұрын
Additive Benefit of Mab in siRNA + IFN-α Combinations - Carey Hwang, MD, PhD
13:07
Additive Benefit of Mab in siRNA + IFN-α Combinations - Carey Hwang, MD, PhD
Ай бұрын
Immunological Editing to Drive HBsAg Production - Adam Gehring, PhD
15:32
Immunological Editing to Drive HBsAg Production - Adam Gehring, PhD
Ай бұрын
RNA Interference Combined with Immune Modulation - Ed Gane, MBChB, MD, FRACP, FAASLD, MNZM
28:19
RNA Interference Combined with Immune Modulation - Ed Gane, MBChB, MD, FRACP, FAASLD, MNZM
Ай бұрын
Пікірлер